Abstract Number: 0772 • ACR Convergence 2023
MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: The gain of function MUC5B rs35705950 promoter variant is the strongest genetic risk factor for the development of RA-ILD (specific to a usual interstitial…Abstract Number: 1466 • ACR Convergence 2023
Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…Abstract Number: 1918 • ACR Convergence 2023
Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality
Background/Purpose: Sarcoidosis is multisystem autoimmune disease characterized by noncaseating granulomas which can result in significant morbidity and mortality. This study aims to identify variables associated…Abstract Number: 2533 • ACR Convergence 2023
Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…Abstract Number: 0180 • ACR Convergence 2023
Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review
Background/Purpose: Lupus results in 58% more organ damage in people of Black race in the US compared to African descendants living in 11 other developed…Abstract Number: 0976 • ACR Convergence 2023
Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis
Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…Abstract Number: 1473 • ACR Convergence 2023
Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades
Background/Purpose: SLE is a chronic autoimmune disease and affects many organ systems. Juvenile onset disease, male sex, renal involvement, and central nervous system involvement are…Abstract Number: 1947 • ACR Convergence 2023
National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England
Background/Purpose: Ethnicity, sex, age & socioeconomic deprivation can all lead to health inequity. Impact of these factors in epidemiology of Idiopathic Inflammatory Myopathies (IIM) has…Abstract Number: 2573 • ACR Convergence 2023
Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) that manifests with interstitial pneumonia and features of autoimmunity while…Abstract Number: 0193 • ACR Convergence 2023
Social Vulnerability Associations with Mortality in a Lupus Cohort
Background/Purpose: The goal of this study is to identify characteristics of socially vulnerable environments associated with increased mortality in a South Carolina systemic lupus erythematosus…Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…Abstract Number: 1482 • ACR Convergence 2023
Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan
Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…Abstract Number: 1953 • ACR Convergence 2023
Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019
Background/Purpose: Patients with polymyositis and dermatomyositis (PM/DM) present multiple complications that may lead to increased mortality rates and data on PM/DM mortality in Mexico is…Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…Abstract Number: 1053 • ACR Convergence 2023
Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 18
- Next Page »